Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying same
US8101175B1 · kind B1 · utility
31Cited by
10References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 20, 2008 |
| Grant date | Jan 24, 2012 |
| Priority date | — |
| Expiry date | Aug 9, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and persistence of Th2 memory when antigen is re-encountered. In an animal model of allergic asthma, inhibiting OX40/OX40L signaling during the secondary response to inhaled antigen suppressed lung inflammation. Inhibiting OX40 at the time of memory cell reactivation reduced the longevity of memory with further inflammation prevented upon tertiary encounter with antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.